open access
Acute central serous chorioretinopathy — an uncommon complication of imatinib mesylate (imatinib) therapy in chronic myelogenous leukaemia
Affiliations- Department of Ophthalmology, Army College of Medical Sciences and Base Hospital, Delhi, India
open access
Abstract
Imatinib is the most widely used drug in targeted therapy for chronic myelogenous leukaemia (CML). Few ophthalmic side effects like periorbital oedema, epiphora, ptosis, extraocular muscle palsy, blepharoconjunctivitis, glaucoma, papilledema, photosensitivity, retinal haemorrhage, and increased intraocular pressure are described with imatinib therapy. A 35-year-old male, a known case of CML with no ocular complaints, on treatment with imatinib for the preceding six weeks, presented with acute central serous chorioretinopathy in the left eye. Owing to his professional requirements for early visual recovery, he was treated with subthreshold micropulse laser with complete resolution of the subretinal fluid. This case report highlights acute central serous chorioretinopathy as a potential rare complication of imatinib therapy in CML patients, which requires regular and detailed ophthalmic evaluation so as to diagnose and treat it without any residual effects.
Abstract
Imatinib is the most widely used drug in targeted therapy for chronic myelogenous leukaemia (CML). Few ophthalmic side effects like periorbital oedema, epiphora, ptosis, extraocular muscle palsy, blepharoconjunctivitis, glaucoma, papilledema, photosensitivity, retinal haemorrhage, and increased intraocular pressure are described with imatinib therapy. A 35-year-old male, a known case of CML with no ocular complaints, on treatment with imatinib for the preceding six weeks, presented with acute central serous chorioretinopathy in the left eye. Owing to his professional requirements for early visual recovery, he was treated with subthreshold micropulse laser with complete resolution of the subretinal fluid. This case report highlights acute central serous chorioretinopathy as a potential rare complication of imatinib therapy in CML patients, which requires regular and detailed ophthalmic evaluation so as to diagnose and treat it without any residual effects.
Keywords
imatinib mesylate (imatinib); chronic myelogenous leukaemia (CML); central serous chorioretinopathy
About this articleTitle
Acute central serous chorioretinopathy — an uncommon complication of imatinib mesylate (imatinib) therapy in chronic myelogenous leukaemia
Journal
Issue
Vol 5 (2020): Continuous Publishing
Article type
Case report
Pages
8-11
Published online
2020-02-06
Page views
702
Article views/downloads
782
DOI
Bibliographic record
Ophthalmol J 2020;5:8-11.
Keywords
imatinib mesylate (imatinib)
chronic myelogenous leukaemia (CML)
central serous chorioretinopathy
Authors
Sanjay Kumar Mishra
Ashok Kumar
References (9)- Singhal MK, Sengar M, Nair R. Summary of the published Indian data on chronic myeloid leukemia. South Asian J Cancer. 2016; 5(3): 162–165.
- O'Brien SG, Guilhot F, Larson RA, et al. IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348(11): 994–1004.
- Rennie I. Ophthalmic manifestations of childhood leukaemia. Br J Ophthalmol. 1992; 76(11): 641.
- Sharma T, Grewal J, Gupta S, et al. Ophthalmic manifestations of acute leukaemias: the ophthalmologist's role. Eye (Lond). 2004; 18(7): 663–672.
- Fraunfelder FW, Solomon J, Druker BJ, et al. Ocular side-effects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther. 2003; 19(4): 371–375.
- Montero J, Cervera E, Palomares P, et al. Serous retinal detachment as a presenting feature of chronic myelogenous leukemia. Retin Cases Brief Rep. 2010; 4(4): 394–396.
- Nakashima S, Kakugawa T, Motomura H, et al. Development of imatinibmesylate-induced interstitial lung disease 2 weeks after discontinuation of the treatment: a case report. Multidiscip Respir Med. 2012; 7(1): 48.
- Thanopoulou E, Judson I. The safety profile of imatinib in CML and GIST: long-term considerations. Arch Toxicol. 2012; 86(1): 1–12.
- Pietras K, Ostman A, Sjöquist M, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 2001; 61(7): 2929–2934.